Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for ANCA-Associated Vasculitis (RAVE)
NCT00104299Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2005
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of rituximab in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2005; status: completed.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT00104299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104299.